We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
-13.7%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.77B
AUM Growth
-$491M
Cap. Flow
+$34.8M
Cap. Flow %
1.96%
Top 10 Hldgs %
50.37%
Holding
141
New
23
Increased
28
Reduced
41
Closed
25

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$70.8M
2
IRON icon
Disc Medicine
IRON
+$59.6M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$25.2M
4
DYN icon
Dyne Therapeutics
DYN
+$19.6M
5
SLNO
Soleno Therapeutics
SLNO
+$18.3M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$70.8M
2
SWTX
SpringWorks Therapeutics
SWTX
+$49.8M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$38.9M
4
ONC
BeOne Medicines Ltd
ONC
+$36.2M
5
CYTK icon
Cytokinetics
CYTK
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 89.75%
2 Technology 5.2%
3 Communication Services 2.41%
4 Consumer Discretionary 1.21%
5 Real Estate 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$6.44B
$297M 16.78%
9,250,005
– –
ONC
2
BeOne Medicines Ltd
ONC
$39.4B
$136M 7.66%
498,689
-155,032
-24% -$36.2M
KYMR icon
3
Kymera Therapeutics
KYMR
$8.94B
$88.7M 5%
3,240,313
+270,580
+9% +$9.86M
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$64.3M 3.63%
+726,167
New +$70.8M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$8.92B
$56.6M 3.19%
1,688,611
+78,959
+5% +$2.95M
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
$56.4M 3.18%
2,578,396
-237,862
-8% -$6.57M
IRON icon
7
Disc Medicine
IRON
$2.97B
$53.2M 3%
+1,071,865
New +$59.6M
SLNO
8
DELISTED
Soleno Therapeutics
SLNO
$52M 2.93%
727,337
+375,519
+107% +$18.3M
ASND icon
9
Ascendis Pharma A/S
ASND
$16.8B
$44.8M 2.53%
287,366
-9,955
-3% -$1.42M
MRUS
10
DELISTED
Merus
MRUS
$43.9M 2.48%
1,043,467
+259,055
+33% +$11.3M
BCAX
11
Bicara Therapeutics
BCAX
$1.84B
$42.6M 2.4%
3,267,083
-5,744
-0.2% -$76.3K
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
$42.6M 2.4%
2,960,029
-44,648
-1% -$731K
NAMS icon
13
NewAmsterdam Pharma
NAMS
$3.34B
$39.1M 2.21%
1,912,030
-183,608
-9% -$4.08M
EWTX icon
14
Edgewise Therapeutics
EWTX
$4.73B
$37.3M 2.11%
1,696,444
+962,101
+131% +$25.2M
ARWR icon
15
Arrowhead Research
ARWR
$12.4B
$34M 1.92%
2,669,880
-231,801
-8% -$4.21M
RNAM
16
DELISTED
Avidity Biosciences
RNAM
$32.8M 1.85%
1,110,610
-16,685
-1% -$520K
WVE icon
17
Wave Life Sciences
WVE
$1.2B
$29.9M 1.68%
3,696,322
-54,169
-1% -$592K
TBLA icon
18
Taboola.com
TBLA
$1.11B
$29.4M 1.66%
9,969,495
– –
DYN icon
19
Dyne Therapeutics
DYN
$4.9B
$28.4M 1.6%
2,717,987
+1,370,531
+102% +$19.6M
SLDB icon
20
Solid Biosciences
SLDB
$900M
$27.4M 1.55%
7,415,905
+3,666,864
+98% +$15.7M
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.12B
$24.6M 1.39%
732,761
-11,008
-1% -$418K
APGE icon
22
Apogee Therapeutics
APGE
$10.2B
$22.2M 1.25%
594,994
-152,331
-20% -$5.89M
RVMD icon
23
Revolution Medicines
RVMD
$44B
$19.9M 1.12%
563,755
-7,793
-1% -$316K
TRVI icon
24
Trevi Therapeutics
TRVI
$2.64B
$18M 1.02%
2,863,793
-42,267
-1% -$202K
VERA icon
25
Vera Therapeutics
VERA
$2.36B
$17.9M 1.01%
747,216
-11,249
-1% -$361K
1
2 3 4 5

Similar funds

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Siren LLC's Q1 2025 Portfolio in Review

As of Q1 2025, Siren LLC held 141 positions worth $1.77B, down 22% from $2.26B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Siren LLC's Q1 2025 filing shows 23 new, 28 increased, 41 reduced and 25 closed positions. Its largest new stake was Blueprint Medicines: 726,167 shares worth $64.3M. The largest sale was argenx, an estimated $70.8M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 93% a quarter earlier, followed by Technology and Communication Services.

  • Siren LLC's largest Q1 2025 buy was Blueprint Medicines: 726,167 shares worth $64.3M.
  • Siren LLC added most to Edgewise Therapeutics in Q1 2025, an estimated $25.2M increase.
  • Siren LLC's biggest Q1 2025 reduction was BeOne Medicines Ltd, cutting an estimated $36.2M.
  • Siren LLC fully exited argenx in Q1 2025, selling an estimated $70.8M.
  • Siren LLC's ten largest holdings make up 50% of its $1.77B portfolio in Q1 2025.
  • Siren LLC opened 23 new positions and closed 25 in Q1 2025.
  • Siren LLC's portfolio value fell 22% quarter-over-quarter to $1.77B.

Based on Siren LLC's 13F filing for Q1 2025, filed 14 May 2025.